Cancer immunotherapy offers substantive benefit to patients with various tumour types, in
some cases leading to complete tumour clearance. However, many patients do not respond …

Immune associated cells in the microenvironment have a significant impact on the
development and progression of hepatocellular carcinoma (HCC) and have received more …

Atezolizumab (anti-programmed death-ligand 1 (PD-L1)) and bevacizumab (anti-vascular
endothelial growth factor (VEGF)) combination therapy has become the new standard of …

The gut microbiota is reported to modulate the immune response in hepatocellular
carcinoma (HCC). Here, we employ metagenomic and metabolomic studies to characterise …

Vascular endothelial growth factor A is known to play a central role in tumor angiogenesis.
Several studies showed that VEGF-A is also an immunosuppressive factor. In tumor-bearing …

Chronic liver injury with any etiology can progress to fibrosis and the end-stage diseases
cirrhosis and hepatocellular carcinoma. The progression of liver disease is controlled by a …

Immunotherapy (eg, cancer vaccines and checkpoint blockades), harnessing the host
immune system to recognize and eradicate tumors, has emerged as one of the most potent …

Liver cancer is highly malignant and insensitive to cytotoxic chemotherapy and is associated
with very poor patient prognosis. In 2007, the small-molecule targeted drug sorafenib was …

Abstract Background & Aims Immune checkpoint inhibitors (ICIs) alone or in combination
with other ICIs or vascular endothelial growth factor pathway inhibitors are therapeutic …

New strategies to decrease risk of relapse after surgery are needed for improving 5‐year
survival rate of hepatocellular carcinoma (HCC). To address this need, a wound‐targeted …